Navigation Links
DelMar Pharmaceuticals to Present Interim Clinical Data for VAL-083 in Glioblastoma at Society of Neuro-Oncology
Date:11/14/2013

, a DNA repair enzyme that causes chemotherapy resistance to front-line treatment with Temodar® (temozolomide).  DelMar is currently studying VAL-083 in a Phase 1/2 clinical trial for patients with refractory glioblastoma multiforme patients. 

About Glioblastoma Multiforme (GBM)
Glioblastoma multiforme (GBM) is the most common and most malignant form of brain cancer. Approximately 15,000 people are diagnosed with glioblastoma each year in the U.S., with similar incidence in Europe. Standard of care is surgery, followed by radiation therapy or combined radiation therapy and chemotherapy with temozolomide. Approximately 60 percent of GBM patients treated with temozolomide experience tumor progression within one year. More than half of glioblastoma patients will fail the currently approved therapies.

About DelMar Pharmaceuticals
DelMar Pharmaceuticals was founded to develop and commercialize proven cancer therapies in new orphan drug indications where patients are failing or have become intolerable to modern targeted or biologic treatments. The Company's lead drug in development, VAL-083, is currently undergoing clinical trials in the U.S. as a potential treatment for refractory glioblastoma multiforme. VAL-083 has been extensively studied by U.S. National Cancer Institute, and is currently approved for the treatment of chronic myelogenous leukemia (CML) and lung cancer in China. Published pre-clinical and clinical data suggest that VAL-083 may be active against a range of tumor types via a novel mechanism of action that could provide improved treatment options for patients.

For more information, please visit www.delmarpharma.com or follow us on Twitter @delmarpharma or Facebook.com/delmarpharma.

Safe Harbor Statement
'/>"/>

SOURCE DelMar Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. DelMar Pharmaceuticals to Present Interim Clinical Data on VAL-083 in Refractory Glioblastoma at Society for Neuro-Oncology (SNO) Annual Meeting
2. DelMar Pharmaceuticals Announces $1.0 Million Third Closing in Private Placement
3. DelMar Pharmaceuticals Announces $1.6 Million Closing in Private Placement
4. DelMar Pharmaceuticals Announces Appointment of John K. Bell to Board of Directors
5. DelMar Pharmaceuticals Announces Completion Of $10.5 Million Oversubscribed Offering And Appointment Of Investor Relations Consultant
6. DelMar Pharmaceuticals to Present at the 25th Annual ROTH Capital Partners Growth Stock Conference
7. DelMar Pharma Named to Rocket Builders 2013"Ready to Rocket" List
8. DelMar Pharmaceuticals to Present Clinical Data from VAL-083 Brain Cancer Trial at the American Association of Cancer Research Annual Meeting
9. DelMar Pharma Presents Encouraging Data From Ongoing Phase I/II GBM Clinical Trial With VAL-083
10. DelMar Pharmaceuticals, Inc. Provides Corporate Update for the Quarter Ended March 31, 2013
11. DelMar Pharmaceuticals to Present Clinical Trials Data for VAL-083 Brain Cancer Trial at the American Society of Clinical Oncology (ASCO) Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2015)... , July 30, 2015  ResMed ... has signed a definitive agreement to acquire ... non-invasive ventilation and sleep-disordered breathing medical devices ... innovation and market reputation in China, combined with ResMed,s global leadership in sleep ... in China suffering ...
(Date:7/30/2015)... edition of #MedicareMonday on Medicare,s 50 th anniversary. As Medicare celebrates 50 years, ... the success of the prescription drug benefit, commonly referred to as Part D. ... videos here: http://onphr.ma/1INp9qQ ... ... More ...
(Date:7/30/2015)... July 30, 2015  Amgen (NASDAQ: AMGN ) today ... managing director of Warburg Pincus LLC, to the Amgen Board ... Fred Hassan and the deep, global experience he ... Robert A. Bradway , chairman and chief executive officer ... will serve Amgen well." Mr. Hassan has been ...
Breaking Medicine Technology:ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 2ResMed Invests in High-Growth Chinese Sleep and Respiratory Care Market with Curative Medical 3Happy 50th Anniversary Medicare! 2Happy 50th Anniversary Medicare! 3Amgen Announces Appointment Of Fred Hassan To Board Of Directors 2Amgen Announces Appointment Of Fred Hassan To Board Of Directors 3
... HealthSouth Corporation (NYSE: HLS ) announced today ... dividend of $16.25 per share on its 6.5% Series A ... holders of record on Oct. 1, 2010. ... rehabilitative healthcare services. Operating in 26 states across the country ...
... Pharmacy announced today they have earned a position of 554 on ... companies in America. "We,re proud to be recognized by ... in the nation, but if you dig a little deeper into ... Phil Hagerman, President and CEO of Diplomat. The details Hagerman refers ...
Cached Medicine Technology:Diplomat Specialty Pharmacy Honored by Inc. Magazine as One of the Nation's Fastest-Growing Companies 2
(Date:8/1/2015)... (PRWEB) , ... August 01, 2015 , ... The condition ... among both men and women often causing pain and discomfort. Those who spend a ... circulatory problem, and Northeast Houston Vein Center is doing what it can to create ...
(Date:8/1/2015)... ... August 01, 2015 , ... Professional Orthopedic ... company has acquired Premier Physical Therapy & Wellness (“Premier”) — with 13 locations ... clinics. , “Our acquisition of Premier Physical Therapy & Wellness solidifies Professional as ...
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on ... and coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the ... allows users to clarify, edit and delete any message including ones already sent. , ...
(Date:7/31/2015)... New York (PRWEB) , ... July 31, 2015 , ... ... strut their stuff, Super-Sod debuted their new type of sod called Leisure Time(TM) ... trademark application in process. , To commemorate introduction of this new type of sod, ...
(Date:7/31/2015)... (PRWEB) , ... July 31, 2015 , ... Precision Aesthetics ... eight years. It was also the first provider of Exilis non-surgical fat reduction ... sought after procedures it has attracted a large International clientele. Many patients travel ...
Breaking Medicine News(10 mins):Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 2Health News:Northeast Houston Vein Center Warns Men about Varicose Veins 3Health News:Professional Physical Therapy Now Largest Outpatient Physical Therapy Provider in Northeast With Acquisition of Premier Physical Therapy & Wellness 2Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Super-Sod Introduces Leisure Time(TM) Zoysia Grass with an Adirondack Chair Promotion 2
... , , , ... NXTM ), a leading manufacturer of innovative dialysis products, today ... his third annual "Grandpa,s Road Trip" with the NxStage(R) System One(TM). ... provides Mr. Wells the opportunity to fit hemodialysis therapy into his ...
... , SILVER SPRING, Md., Sept. 18 The U.S. ... O Plus assay, as a screening tool designed to detect the presence ... that run on the fully automated Abbott Prism System. , , ... There are two types of HIV. HIV type 1 consists ...
... LOUDOUN COUNTY, Va., Sept. 18 On Sunday, ... wellness partner GlaxoSmithKline, and Men,s Health Network (MHN), will recognize ... awareness ribbons and disease awareness information cards to fans prior ... FedExField. Led by MHN staff, volunteers from GlaxoSmithKline, Sigma Phi ...
... abuse among those who could drink before 21 , FRIDAY, ... a place and time when they could legally buy alcohol ... alcoholics or have a drug problem, even well into adulthood, ... Dr. Karen Norberg, a research instructor in psychiatry at Washington ...
... , , , ... pioneer and leader in the development of Optical Coherence Tomography ... will showcase its advanced FD-OCT(TM) technology, the C7-XR(TM) imaging system, ... CA starting Monday, September 21 through Friday, September 25, 2009. ...
... less cost, study suggests , FRIDAY, Sept. 18 (HealthDay News) ... into signs of heart disease by using cardiac CT scans ... CT scans use X-rays to create cross-sectional images of the ... arteries, but it,s hard to tell if they,re actually preventing ...
Cached Medicine News:Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 2Health News:NxStage Patient Takes Dialysis Machine on Third Annual Patient Good-Will Tour 3Health News:Men's Health Network, The Washington Redskins and GlaxoSmithKline Team Up for September's Prostate Cancer Awareness Month 2Health News:Lower Drinking Age Linked to Later-Life Problems 2Health News:Lower Drinking Age Linked to Later-Life Problems 3Health News:LightLab(R) Imaging Showcases Advanced OCT System Technology at TCT 2009 2Health News:LightLab(R) Imaging Showcases Advanced OCT System Technology at TCT 2009 3Health News:Researchers Perfect the View of Heart Disease 2
Bayonet fine, smooth - 1/box....
Blunt, with attached cable for Valleylab and other brands generators....
Bipolar hand activated forceps....
Blunt, 20 cm long....
Medicine Products: